☆ 4.2 Review

Evidence-based Management of Major Bleeding in Patients Receiving Direct Oral Anticoagulants: An Updated Narrative Review on the Role of Specific Reversal Agents

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2023)

Related references

Note: Only part of the references are listed.

Article Cardiac & Cardiovascular Systems

Final Study Report of Andexanet Alfa for Major Bleeding With Factor Xa Inhibitors

Jr Tuman J. Milling et al.

Summary: This study evaluated the safety and efficacy of andexanet alfa in patients with major bleeding caused by factor Xa inhibitors. The results showed that the drug reduced anti-FXa activity and achieved good or excellent hemostatic efficacy in 80% of the patients.

CIRCULATION (2023)

Add to Collection

Review Emergency Medicine

Management of major bleeding for anticoagulated patients in the Emergency Department: an European experts consensus statement

Barbra Backus et al.

Summary: This article provides a systematic and practical approach for managing anticoagulated patients with severe bleeding in the emergency department. It discusses in detail the repletion and reversal management of different types of anticoagulants, as well as specific treatment strategies for different clinical situations.

EUROPEAN JOURNAL OF EMERGENCY MEDICINE (2023)

Add to Collection

Article Medicine, General & Internal

Time Trends and Treatment Pathways in Prescribing Individual Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation: An Observational Study of More than Three Million Patients from Europe and the United States

Pareen Vora et al.

Summary: The use of oral anticoagulants among patients with atrial fibrillation has significantly changed from 2010 to 2017 in the US and Europe. Vitamin K antagonists have declined while direct oral anticoagulants have increased. Apixaban has become the most commonly prescribed anticoagulant.

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2022)

Add to Collection

Article Cardiac & Cardiovascular Systems

Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

Gregory Y. H. Lip et al.

Summary: This study compared the safety and effectiveness of different non-vitamin K antagonists (NOACs) in newly diagnosed atrial fibrillation (AF) patients. The results showed that dabigatran had a lower risk of major bleeding compared to rivaroxaban, but similar risks of stroke, myocardial infarction (MI), and death. Patients treated with dabigatran had similar risks of stroke, major bleeding, MI, and death compared to apixaban. Rivaroxaban had an increased risk of major bleeding compared to apixaban, but similar risks of stroke, MI, and death.

CLINICAL RESEARCH IN CARDIOLOGY (2022)

Add to Collection

Article Critical Care Medicine

Perioperative Anticoagulation Management

Lauren D. Briete et al.

Summary: Managing anticoagulation during operative procedures is a complex task with limited guidance. This review summarizes the available literature on assessment, monitoring, timing of adjusting anticoagulation, and bridging prior to procedures. It also discusses perioperative management in special populations and provides principles for resuming anticoagulation.

CRITICAL CARE NURSING QUARTERLY (2022)

Add to Collection

Article Pharmacology & Pharmacy

Trends of use and factors that determine the choice of oral anticoagulants in women and men with atrial fibrillation

Aurelie Lenglet et al.

Summary: The study aims to identify sex-specific factors associated with the initiation of oral anticoagulants in patients with atrial fibrillation. Administrative data from Quebec between 2014 and 2017 were used. The results showed a decrease in the use of warfarin and an increase in the use of DOACs, with the year of initiation being a major factor. In addition, women were more likely to receive low-dose DOACs.

PHARMACOLOGY RESEARCH & PERSPECTIVES (2022)

Add to Collection

Review Hematology

Interplay between platelets and coagulation

Yaqiu Sang et al.

Summary: Haemostasis is a regulated physiological process involving interactions between endothelial cells, platelets, von Willebrand factor, and coagulation factors. Platelets and coagulation mutually influence each other to effectively stop bleeding by forming a platelet plug.

BLOOD REVIEWS (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study

Joris R. de Groot et al.

Summary: The study in Europe on the routine care of atrial fibrillation patients treated with edoxaban for 1 year showed that the drug is effective in preventing stroke, systemic embolism, and major bleeding in high-risk atrial fibrillation patients, with good safety profile.

EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Laboratory Monitoring of Direct Oral Anticoagulants (DOACs)

Claire Dunois

Summary: Direct oral anticoagulants (DOACs) provide a safe and effective alternative to previous anticoagulant therapies by directly, selectively, and reversibly inhibiting factors IIa or Xa. They have predictable pharmacokinetic and pharmacodynamic responses at a fixed dose, eliminating the need for monitoring. Testing may be helpful for patient management in specific clinical situations and for particular patient populations.

BIOMEDICINES (2021)

Add to Collection

Article Medicine, General & Internal

Knowledge of Anticoagulation Among Saudi Patients With Atrial Fibrillation: A Cross-Sectional Study

Hamdan N. Alajami et al.

Summary: This study found significant knowledge gaps among Saudi patients with atrial fibrillation taking oral anticoagulants. Advancing age was inversely associated with oral anticoagulation knowledge.

CUREUS JOURNAL OF MEDICAL SCIENCE (2021)

Add to Collection

Article Hematology

Performance Characteristics of DOAC Dipstick in Determining Direct Oral Anticoagulants in Urine

Job Harenberg et al.

Summary: Testing for DOACs in urine can help with medical treatment decisions, and the DOAC Dipstick test showed 100% accuracy in detecting factor Xa and thrombin inhibitors. The test pads did not react to other anticoagulants like heparins and coumadin, and abnormal urine colors were reliably detected.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants

Niklas Wallvik et al.

Summary: The study revealed that elderly patients and those with a history of major bleeding, COPD, previous stroke, or TIA have a higher risk of major bleeding when treated with NOACs for VTE. Prior warfarin treatment was shown to be protective in preventing major bleeding in this patient population.

JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2021)

Add to Collection

Article Medicine, General & Internal

Effectiveness and safety of rivaroxaban versus warfarin in obese nonvalvular atrial fibrillation patients: analysis of electronic health record data

Olivia S. Costa et al.

CURRENT MEDICAL RESEARCH AND OPINION (2020)

Add to Collection

Review Medicine, Research & Experimental

New oral anticoagulants - possible extension to other indications (Review)

Crista Loredana Laslo et al.

EXPERIMENTAL AND THERAPEUTIC MEDICINE (2020)

Add to Collection

Article Medicine, Research & Experimental

Evaluation of the Incremental Healthcare Economic Burden of Patients with Atrial Fibrillation Treated with Direct-Acting Oral Anticoagulants and Hospitalized for Major Bleeds in the USA

Steven B. Deitelzweig et al.

ADVANCES IN THERAPY (2020)

Add to Collection

Review Pharmacology & Pharmacy

Prevention and Treatment of Bleeding with Direct Oral Anticoagulants

R. Monroe Crawley et al.

DRUGS (2020)

Add to Collection

Review Cardiac & Cardiovascular Systems

Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges

Ashley Chen et al.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants A Report of the American College of Cardiology Solution Set Oversight Committee

Gordon F. Tomaselli et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)

Add to Collection

Review Pharmacology & Pharmacy

Andexanet Alfa: A Recombinant Modified Human Factor Xa Protein for Drug Reversal of Rivaroxaban and Apixaban

Irene Abuan et al.

JOURNAL OF PHARMACY TECHNOLOGY (2019)

Add to Collection

Article Clinical Neurology

European Stroke Organisation Guideline on Reversal of Oral Anticoagulants in Acute Intracerebral Haemorrhage

Hanne Christensen et al.

EUROPEAN STROKE JOURNAL (2019)

Add to Collection

Article Hematology

Betrixaban: Impact on Routine and Specific Coagulation Assays-A Practical Laboratory Guide

Romain Siriez et al.

THROMBOSIS AND HAEMOSTASIS (2018)

Add to Collection

Article Clinical Neurology

Cardioembolic Stroke Risk and Recovery After Anticoagulation-Related Intracerebral Hemorrhage

Meredith P. Murphy et al.

STROKE (2018)

Add to Collection

Article Cardiac & Cardiovascular Systems

XANTUS-EL: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Eastern Europe, Middle East, Africa and Latin America

Carlos Arturo Arean Martinez et al.

EGYPTIAN HEART JOURNAL (2018)

Add to Collection

Review Peripheral Vascular Disease

Reversal of direct oral anticoagulants

Mosaad Almegren

VASCULAR HEALTH AND RISK MANAGEMENT (2017)

Add to Collection

Article Critical Care Medicine

Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants

Bethany T. Samuelson et al.

CHEST (2017)

Add to Collection

Review Hematology

Measurement and reversal of the direct oral anticoagulants

Bethany T. Samuelson et al.

BLOOD REVIEWS (2017)

Add to Collection

Review Hematology

Reversing factor Xa inhibitors - clinical utility of andexanet alfa

Scott Kaatz et al.

JOURNAL OF BLOOD MEDICINE (2017)

Add to Collection

Article Emergency Medicine

Safety of a Four-factor Prothrombin Complex Concentrate Versus Plasma for Vitamin K Antagonist Reversal: An Integrated Analysis of Two Phase IIIb Clinical Trials

Truman J. Milling et al.

ACADEMIC EMERGENCY MEDICINE (2016)

Add to Collection

Review Anesthesiology

Management of direct oral anticoagulants-associated bleeding in the trauma patient

Christian von Heymann et al.

CURRENT OPINION IN ANESTHESIOLOGY (2016)

Add to Collection

Review Chemistry, Medicinal

Spotlight on idarucizumab and its potential for the reversal of anticoagulant effects of dabigatran

Pierre Sie

DRUG DESIGN DEVELOPMENT AND THERAPY (2016)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation

Xiaoxi Yao et al.

JOURNAL OF THE AMERICAN HEART ASSOCIATION (2016)

Add to Collection

Review Cardiac & Cardiovascular Systems

Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review

Adam Cuker et al.

JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2015)

Add to Collection

Review Clinical Neurology

Guidelines for the Management of Spontaneous Intracerebral Hemorrhage A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association

J. Claude Hemphill et al.

STROKE (2015)

Add to Collection

Article Hematology

Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran

Charles V. Pollack et al.

THROMBOSIS AND HAEMOSTASIS (2015)

Add to Collection

Review Nutrition & Dietetics

New Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs)

Rick H. van Gorp et al.

NUTRIENTS (2015)

Add to Collection

Article Health Care Sciences & Services

New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events

Agon Mekaj et al.

Therapeutics and Clinical Risk Management (2015)

Add to Collection

Article Cardiac & Cardiovascular Systems

Laboratory Measurement of the Anticoagulant Activity of the Non-Vitamin K Oral Anticoagulants

Adam Cuker et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2014)

Add to Collection

Article Hematology

Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta- analysis

T. van der Hulle et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2014)

Add to Collection

Article Cardiac & Cardiovascular Systems

Efficacy and Safety of a 4-Factor Prothrombin Complex Concentrate in Patients on Vitamin K Antagonists Presenting With Major Bleeding A Randomized, Plasma-Controlled, Phase IIIb Study

Ravi Sarode et al.

CIRCULATION (2013)

Add to Collection

Review Hematology

Concept of a point of care test to detect new oral anticoagulants in urine samples

Job Harenberg et al.

THROMBOSIS JOURNAL (2013)

Add to Collection

Article Cardiac & Cardiovascular Systems

Standardized Bleeding Definitions for Cardiovascular Clinical Trials A Consensus Report From the Bleeding Academic Research Consortium

Roxana Mehran et al.

CIRCULATION (2011)

Add to Collection

© Peeref 2019-2024. All rights reserved.